人卵巢癌細(xì)胞

簡(jiǎn)要描述：HTB-77 SK-OV-3 人卵巢癌細(xì)胞，
ATCC 細(xì)胞|細(xì)胞系|細(xì)胞株|腫瘤細(xì)胞|細(xì)胞,細(xì)胞庫管理規(guī)范，
提供的細(xì)胞株背景清楚,提供參考文獻(xiàn)和培養(yǎng)條件

產(chǎn)品型號(hào)：SK-OV-3
廠商性質(zhì)：生產(chǎn)廠家
更新時(shí)間：2025-09-11
訪問量：2671

產(chǎn)品咨詢聯(lián)系我們

產(chǎn)品分類

Product Category

細(xì)胞庫

細(xì)胞原代牛、狗、雞、鴨、魚原代細(xì)胞羊原代細(xì)胞豬原代細(xì)胞兔原代細(xì)胞小鼠原代細(xì)胞大鼠原代細(xì)胞人原代細(xì)胞培養(yǎng)基原代細(xì)胞凍存液 ATCC 人乳腺癌豬正常細(xì)胞豬睪丸細(xì)胞系人膠質(zhì)瘤細(xì)胞人成骨細(xì)胞人永生化肝細(xì)胞人肝癌細(xì)胞人卵巢癌細(xì)胞人結(jié)直腸腺癌人經(jīng)典小細(xì)胞肺癌細(xì)胞人小細(xì)胞肺癌細(xì)胞人結(jié)直腸腺癌細(xì)胞人鼻腔上皮細(xì)胞中國(guó)倉鼠卵巢懸浮細(xì)胞嗜性逆轉(zhuǎn)錄病毒包裝穩(wěn)定細(xì)胞株小鼠神經(jīng)細(xì)胞瘤人眼脈洛膜黑色素瘤 PT67 逆轉(zhuǎn)錄酶病毒包裝細(xì)胞鴨子胚胎成纖維細(xì)胞豬腎細(xì)胞系昆蟲細(xì)胞貓腎細(xì)胞恒河猴胚腎細(xì)胞倉鼠卵巢細(xì)胞負(fù)鼠腎細(xì)胞倉鼠肺細(xì)胞果蠅胚胎細(xì)胞家貓肺成纖維樣細(xì)胞雞胚細(xì)胞豚鼠心肌來源細(xì)胞豚鼠肺成纖維樣細(xì)胞豚鼠皮膚成纖維樣細(xì)胞狗腎細(xì)胞非洲綠猴胚胎腎上皮細(xì)胞猴胚胎腎上皮細(xì)胞長(zhǎng)臂猿淋巴瘤新生牛眼囊成纖維細(xì)胞黑化大家鼠肺成纖維樣細(xì)胞俄勒岡地鼠細(xì)胞家兔皮膚成纖維樣細(xì)胞昆蟲卵巢細(xì)胞人胸膜瘤細(xì)胞非洲綠猴腎細(xì)胞 VERO 衍生株（SVP）白化金黃地鼠肺成纖維樣細(xì)胞黃胸鼠肺成纖維樣細(xì)胞白鰱尾鰭細(xì)胞蝙蝠肺細(xì)胞草魚腎細(xì)胞系大黃魚腎細(xì)胞猴腎細(xì)胞系犬腎細(xì)胞系人結(jié)腸直腸腺癌豬肺泡巨噬細(xì)胞 PFHSA05（TLL2）人重組特洛德樣蛋白因子 PFHSA04 （BMP1）人重組骨誘導(dǎo)因子人乳腺癌細(xì)胞結(jié)腸癌細(xì)胞成纖維細(xì)胞人胚腎細(xì)胞動(dòng)物卵巢細(xì)胞動(dòng)物胚胎細(xì)胞動(dòng)物肺細(xì)胞肋骨來源細(xì)胞成纖維樣細(xì)胞動(dòng)物上皮細(xì)胞動(dòng)物肝臟細(xì)胞可誘導(dǎo)表達(dá)穩(wěn)定細(xì)胞株動(dòng)物氣管細(xì)胞動(dòng)物腎細(xì)胞動(dòng)物巨噬細(xì)胞人正常細(xì)胞人腫瘤細(xì)胞、癌細(xì)胞小鼠正常細(xì)胞小鼠腫瘤細(xì)胞、癌細(xì)胞大鼠正常細(xì)胞大鼠腫瘤細(xì)胞其它動(dòng)物細(xì)胞查看全部產(chǎn)品

相關(guān)文章

詳細(xì)介紹

HTB-77 SK-OV-3 人卵巢癌細(xì)胞

ATCC® Number: HTB-77™ Price: $272.00

Designations: SK-OV-3 [SKOV-3]

Depositors: G Trempe, LJ Old

Biosafety Level: 1

Shipped: frozen

Medium & Serum: See Propagation

Growth Properties: adherent

Organism: Homo sapiens （human）

Morphology: epithelial

HTB-77 SK-OV-3 人卵巢癌細(xì)胞

Source: Organ: ovary

Disease: adenocarcinoma

Derived from metastatic site: ascites

Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimay responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.

Restrictions: The cells are distributed for research purposes only. The Memorial Sloan-Kettering Cancer Center releases the line subject to the following: 1.） The cells or their products must not be distributed to third parties. Commercial interests are the exclusive property of Memorial Sloan-Kettering Cancer Center. 2.） Any proposed commercial use of these cells must first be negotiated with The Director, Office of Industrial Affairs, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021; phone （212） 639-6181; （212） 717-3439.

Isolation: Isolation date: 1973

Applications: transfection host （Nucleofection technology from Lonza

Roche FuGENE® Transfection Reagents）

Tumorigenic: Yes

Antigen Expression: Blood Type B; Rh+

DNA Profile （STR）: Amelogenin: X

CSF1PO: 11

D13S317: 8,11

D16S539: 12

D5S818: 11

D7S820: 13,14

THO1: 9,9.3

TPOX: 8,11

vWA: 17,18

Cytogenetic Analysis: This is a hypodiploid human cell line. The modal chromosome number was 43, occurring in 63.3% of cells. The range was 42 to 45. The rate of higher ploidies was 32%. The del（1）（q21）, der（13）t（1;?;13）（q11;?;q34）, der（11）t（11;?）（q12）, del（10）（q22） and 3 other marker chromosomes were common to most cells, and 3 others were found only in some cells. One N11 had the HSR segment from p11 to the distal end. The normal N10, N12, N15, N17 and N19 were absent. Others were either single or paired. There were from 1 to 6 rearranged and unassignable chromosomes. The X chromosome was either single or paired.

Isoenzymes: AK-1, 1

ES-D, 1

G6PD, B

GLO-I, 1-2

Me-2, 1

PGM1, 1-2

PGM3, 1

Age: 64 years

Gender: female

Ethnicity: Caucasian

Comments: SK-OV-3 cells are resistant to tumor necrosis factor and to several cytotoxic drugs including diphtheria toxin, cis-platinum and adriamycin.

Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated McCoy's 5a Medium Modified, Catalog No. 30-2007. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.

Atmosphere: air, 95%; carbon dioxide （CO2）, 5%

Temperature: 37.0°C

Subculturing: Protocol:

1.Remove and discard culture medium.

2.Briefly rinse the cell layer with 0.25% （w/v） Trypsin- 0.53 mM EDTA solution to remove all traces of serum that contains trypsin inhibitor.

3.Add 2.0 to 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed （usually within 5 to 15 minutes）.

Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.

4.Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting.

5.Add appropriate aliquots of the cell suspension to new culture vessels.

6.Incubate cultures at 37°C.

Subc*tion Ratio: A subc*tion ratio of 1:2 to 1:6 is recommended

Medium Renewal: 2 to 3 times per week

Preservation: Freeze medium: Complete growth medium supplemented with 5% （v/v） DMSO

Storage temperature: liquid nitrogen vapor phase

Related Products: Recommended medium （without the additional supplements or serum described under ATCC Medium）:ATCC 30-2007

recommended serum:ATCC 30-2020

References: 21869: . Human tumor cells in vitro. New York: Plenum Press; 1975.

22536: Fogh J, et al. Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J. Natl. Cancer Inst. 58: 209-214, 1977. PubMed: 833871

22539: Fogh J, et al. One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J. Natl. Cancer Inst. 59: 221-226, 1977. PubMed: 327080

23103: Morimoto H, et al. Overcoming tumor necrosis factor and drug resistance of human tumor cell lines by combination treatment with anti-Fas antibody and drugs or toxins. Cancer Res. 53: 2591-2596, 1993. PubMed: 7684321

23478: Morimoto H, et al. Synergistic effect of tumor necrosis factor-alpha- and diphtheria toxin- mediated cytotoxicity in sensitive and resistant human ovarian tumor cell lines. J. Immunol. 147: 2609-2616, 1991. PubMed: 1918981

32281: Zhang X, et al. Microfilament depletion and circumvention of multiple drug resistance by sphinxolides. Cancer Res. 57: 3751-3758, 1997. PubMed: 9288783

32456: Clinton GM, et al. Estrogens increase the expression of fibulin-1, an extracellular matrix protein secreted by human ovarian cancer cells. Proc. Natl. Acad. Sci. USA 93: 316-320, 1996. PubMed: 8552629

32530: Zhang X, Smith CD. Microtubule effects of welwistatin, a cyanobacterial indolinone that circumvents multiple drug resistance. Mol. Pharmacol. 49: 288-294, 1996. PubMed: 8632761

90272: Wiechen K, et al. Suppression of the c-erbB-2 gene product decreases transformation abilities but not the proliferation and secretion of proteases of SK-OV-3 ovarian cancer cells. Br. J. Cancer 81: 790-795, 1999. PubMed: 10555747

90273: Yu D, et al. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A. Cancer Res. 53: 891-898, 1993. PubMed: 8094034

90274: Karlan BY, et al. Glucocorticoids stabilize HER-2/neu messenger RNA in human epithelial ovarian carcinoma cells. Gyn. Onc. 53: 70-77, 1994. PubMed: 7909787

HTB-77 SK-OV-3

產(chǎn)品咨詢

留言框

產(chǎn)品：
您的單位：
您的姓名：
聯(lián)系電話：
常用郵箱：
省份：
詳細(xì)地址：
補(bǔ)充說明：
驗(yàn)證碼：

請(qǐng)輸入計(jì)算結(jié)果（填寫阿拉伯?dāng)?shù)字），如：三加四=7

上一篇：MCF-10A人正常乳腺上皮細(xì)胞
下一篇：MEG-01人成巨核細(xì)胞白血病細(xì)胞

人卵巢癌細(xì)胞

留言框

產(chǎn)品：

您的單位：

您的姓名：

聯(lián)系電話：

常用郵箱：

省份：

詳細(xì)地址：

補(bǔ)充說明：

驗(yàn)證碼：